US 2022/0089746 A1Published application

Galectin-7-specific monovalent antibodies and uses thereof

AssigneeInstitut National De La Recherche Scientifique

InventorsDavid Chatenet, Nicolas Doucet, Yves St-Pierre

Life of this patent

Estimating the term…

Abstract

Monovalent antibodies such as nanobodies that are specific for galectin-7 are described. These monovalent antibodies are able to interfere with the dimerization of galectin-7, and thus may be used for the treatment of diseases associated with dysregulated galectin-7 expression and/or activity, such as certain types of cancers as well as eye diseases or conditions associated with pathological neovascularization or angiogenesis.

Claims31

Dependent claims

A monovalent antibody that specifically binds to human galectin-7 (hGAL-7), wherein the monovalent antibody comprises one of the following combinations of complementarity determining regions (CDRs):

(a) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence AGSRSDV (SEQ ID NO:12);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence GFWGWTT (SEQ ID NO:13);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence LGGAPGQTG (SEQ ID NO:14);
(b) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence DTSRFDV (SEQ ID NO:15);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence WWSSDHI (SEQ ID NO:16);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence YGEYPPRMNRRP (SEQ ID NO:17);
(c) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence TTSNSSG (SEQ ID NO:18);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence WDHGILT (SEQ ID NO:19);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence HGYVHFNMTHRHISD (SEQ ID NO:20);
(d) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence TTSNGEV (SEQ ID NO:21);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence FGAGSSE (SEQ ID NO:22);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence ASWYHSSIGSMS (SEQ ID NO:23);
(e) a CDR1 comprising or consisting of an amino acid sequence having at least 80% identity with the sequence AYSFESG (SEQ ID NO:24);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence SDADLFS (SEQ ID NO:25);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence AFSSGGELS (SEQ ID NO:26);
(f) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence RYSRIEI (SEQ ID NO:27);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence STPSSNE (SEQ ID NO:28);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence RWDWHSWDT (SEQ ID NO:29);
(g) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence STSYSST (SEQ ID NO:30);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence FDGTSKP (SEQ ID NO:31);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence AGEWEALMWPPVHDFWIY (SEQ ID NO:32);
(h) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence RTSSQDI (SEQ ID NO:33);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence DYSGGNV (SEQ ID NO:34);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence FLGEEKTSW (SEQ ID NO:35);
(i) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence STSYGET (SEQ ID NO:36);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence YYSTRKP (SEQ ID NO:37);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence IVAYIYADGVRGYHQKID (SEQ ID NO:38);
(j) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence GGYDWDA (SEQ ID NO:39);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence SNNNGSR (SEQ ID NO:40);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence ADQ (SEQ ID NO 41);
(k) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence TYSSIEV (SEQ ID NO:42);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence FEPNEFA (SEQ ID NO:43);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence SSVEWRQNGKPNTAS (SEQ ID NO:44);
or
(l) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence DTSESTS (SEQ ID NO:45);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence RSSTWDA (SEQ ID NO:46);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence MADIFDHPQNASFMK (SEQ ID NO:47).

34 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/421,476Filed 9 Jan 2020
Priority: 9 Jan 2019
Published: 24 Mar 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61P 27/02
Drugs for disorders of the senses: ophthalmic agents
A61P 35/00
Antineoplastic agents
G01N 33/533
Production of labelled immunochemicals: with fluorescent label

Family

Application62/790,197Us provisional application · filed 9 Jan 2019
US 12,195,541 B2Related patent
US 2022/0089746 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

A monovalent antibody that specifically binds to human galectin-7 (hGAL-7), wherein the monovalent antibody comprises one of the following combinations of complementarity determining regions (CDRs):

(a) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence AGSRSDV (SEQ ID NO:12);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence GFWGWTT (SEQ ID NO:13);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence LGGAPGQTG (SEQ ID NO:14);
(b) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence DTSRFDV (SEQ ID NO:15);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence WWSSDHI (SEQ ID NO:16);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence YGEYPPRMNRRP (SEQ ID NO:17);
(c) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence TTSNSSG (SEQ ID NO:18);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence WDHGILT (SEQ ID NO:19);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence HGYVHFNMTHRHISD (SEQ ID NO:20);
(d) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence TTSNGEV (SEQ ID NO:21);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence FGAGSSE (SEQ ID NO:22);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence ASWYHSSIGSMS (SEQ ID NO:23);
(e) a CDR1 comprising or consisting of an amino acid sequence having at least 80% identity with the sequence AYSFESG (SEQ ID NO:24);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence SDADLFS (SEQ ID NO:25);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence AFSSGGELS (SEQ ID NO:26);
(f) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence RYSRIEI (SEQ ID NO:27);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence STPSSNE (SEQ ID NO:28);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence RWDWHSWDT (SEQ ID NO:29);
(g) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence STSYSST (SEQ ID NO:30);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence FDGTSKP (SEQ ID NO:31);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence AGEWEALMWPPVHDFWIY (SEQ ID NO:32);
(h) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence RTSSQDI (SEQ ID NO:33);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence DYSGGNV (SEQ ID NO:34);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence FLGEEKTSW (SEQ ID NO:35);
(i) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence STSYGET (SEQ ID NO:36);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence YYSTRKP (SEQ ID NO:37);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence IVAYIYADGVRGYHQKID (SEQ ID NO:38);
(j) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence GGYDWDA (SEQ ID NO:39);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence SNNNGSR (SEQ ID NO:40);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence ADQ (SEQ ID NO 41);
(k) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence TYSSIEV (SEQ ID NO:42);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence FEPNEFA (SEQ ID NO:43);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence SSVEWRQNGKPNTAS (SEQ ID NO:44);
or
(l) a CDR1 comprising an amino acid sequence having at least 80% identity with the sequence DTSESTS (SEQ ID NO:45);
a CDR2 comprising an amino acid sequence having at least 80% identity with the sequence RSSTWDA (SEQ ID NO:46);
and a CDR3 comprising an amino acid sequence having at least 80% identity with the sequence MADIFDHPQNASFMK (SEQ ID NO:47).

34 more elements

Facts

Application

17/421,476Filed 9 Jan 2020

Priority

9 Jan 2019

Published

24 Mar 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61P 27/02
Drugs for disorders of the senses: ophthalmic agents
A61P 35/00
Antineoplastic agents
G01N 33/533
Production of labelled immunochemicals: with fluorescent label